Search results
Showing 601 to 650 of 8897 results
Up to 1,000 women a year could benefit from new at-home treatment for endometriosis
Today we've recommended a new treatment option for symptoms of endometriosis that can be taken at home.
Evidence-based recommendations on capivasertib (Truqap) with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment in adults.
AI skin cancer detection system gets green light for conditional NHS use
An artificial intelligence system for potential skin cancer has been conditionally recommended for use in the NHS for the next three years while further evidence is collected.
Health inequalities - an update to NICE's methods for health technology evaluation
Our new modular update focuses on how we consider health inequalities when evaluating technologies for use in the NHS, and how you can get involved in suggesting future updates.
Evidence-based recommendations on erdafitinib (Balversa) for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitor in adults.
Show all sections
Technology recommended for people with chronic tic disorders and Tourette syndrome
Final guidance recommends one digital therapy to help children and young people manage their condition.
Evidence-based recommendations on osimertinib (Tagrisso) with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer in adults.
Evidence-based recommendations on brentuximab vedotin (Adcetris) for untreated stage 3 or 4 CD30-positive Hodgkin lymphoma in adults.
Digital therapy for chronic tic disorders and Tourette syndrome: early value assessment (HTG748)
Early value assessment (EVA) guidance on digital therapy for chronic tic disorders and Tourette syndrome.
Home Get involved...
Home Get involved...
NICE is unable to make a recommendation on omaveloxolone (Skyclarys) for treating Friedreich’s ataxia in people 16 years and over. This is because Biogen withdrew its evidence submission.
Show all sections
Sections for TA1061
Drug-eluting stents for treating coronary artery disease: late-stage assessment (HTG747)
Late-stage assessment (LSA) guidance on drug-eluting stents for treating coronary artery disease.
View recommendations for HTG747Show all sections
Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 (TA878)
Evidence-based recommendations on nirmatrelvir plus ritonavir (Paxlovid), sotrovimab (Xevudy) and tocilizumab (RoActemra) for treating COVID-19.
This guideline covers managing COVID-19 in babies, children, young people and adults in community and hospital settings. It includes recommendations on communication, assessment, therapeutics for COVID-19, non-invasive respiratory support, preventing and managing acute complications, and identifying and managing co-infections.
Early value assessment (EVA) guidance on artificial intelligence (AI) technologies for assessing and triaging skin lesions referred to the urgent suspected skin cancer pathway.
Home Implementing NICE guidance Social care Using NICE guidance in social work: scenarios Services for older people {"@context":"http://schema.org"
Home Implementing NICE guidance Social care Using NICE guidance in social work: scenarios for principle social workers Positive workplaces for social
Home Implementing NICE guidance Social care Using NICE guidance in social work: scenarios for principle social workers Positive workplaces for social
Home Implementing NICE guidance Social care Using NICE guidance in social work: scenarios for principle social workers Positive workplaces for social
Slide sheets for moving or repositioning a person: late-stage assessment (HTG745)
Late-stage assessment (LSA) guidance on slide sheets for moving or repositioning a person.
Home Implementing NICE guidance Social care Using NICE guidance in social work: scenarios Services for older people {"@context":"http://schema.org"
This indicator covers the proportion of people aged 60 and over admitted to hospital with hip fracture, who receive a comprehensive falls assessment. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG22
This indicator covers the percentage of patients (aged 65 years and over) with moderate or severe frailty who have been asked whether they have had a fall, about the total number of falls and about the type of falls, in the last 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM187
Falls: assessment and prevention in older people and in people 50 and over at higher risk (NG249)
This guideline covers assessing risk of falling and interventions to prevent falls in all people aged 65 and over, and people aged 50 to 64 who are at higher risk of falls. It aims to reduce the risk and incidence of falls, and the associated distress, pain, injury, loss of confidence, loss of independence and mortality.
This quality standard covers prevention of falls and assessment after a fall in people who are living in the community, in a residential care setting or staying in hospital and are:
View quality statements for QS86Show all sections
Sections for QS86
- Quality statements
- Quality statement 1: Asking people about falls
- Quality statement 2: Comprehensive falls assessment
- Quality statement 3: Interventions to reduce the risk of falls
- Quality statement 4: Checks for injury after an inpatient fall
- Quality statement 5: Safe manual handling after an inpatient fall
- Quality statement 6: Medical examination after an inpatient fall
- Quality statement 7: Multifactorial risk assessment for older people presenting for medical attention
New guideline will help cut falls and related hospital admissions for older and at-risk people
Personalised assessments that consider factors including the hazards in a person’s home, and their previous medical history will help reduce falls in older and at-risk people, according to a new NICE guideline.
NICE is unable to make a recommendation on tislelizumab (Tevimbra) in combination for untreated advanced non-small-cell lung cancer in adults. This is because the company did not provide an evidence submission.
Show all sections
Sections for TA1058
Evidence-based recommendations on leniolisib (Joenja) for treating activated phosphoinositide 3-kinase delta syndrome in people 12 years and over.
Evidence-based recommendations on balloon disimpaction of the baby’s head at emergency caesarean during the second stage of labour. This involves inserting a silicone balloon into the vagina and inflating to lift the baby’s head before starting the caesarean.
Cutting-edge robotic surgery gets green light as 11 systems are recommended
Eleven cutting-edge robotic surgery systems have been approved for use, potentially transforming care for thousands of NHS patients undergoing soft tissue and orthopaedic procedures.
Robot-assisted surgery for orthopaedic procedures: early value assessment (HTG743)
Early value assessment (EVA) guidance on robot-assisted surgery for orthopaedic procedures.
Robot-assisted surgery for soft tissue procedures: early value assessment (HTG742)
Early value assessment (EVA) guidance on robot-assisted surgery for soft tissue procedures.
Diabetes: annual psychological assessment (children T2DM) (IND314)
This indicator covers the proportion of children and young people aged under 18 years with type 2 diabetes who have received a psychological assessment in the previous 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
Diabetes: annual psychological assessment (children T1DM) (IND313)
This indicator covers the proportion of children and young people aged under 18 years with type 1 diabetes who have received a psychological assessment in the previous 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
Diabetes: thyroid disease screening (children T1DM) (IND312)
This indicator covers the proportion of children and young people aged under 18 years with type 1 diabetes who have been screened for thyroid disease in the previous 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
This indicator covers the proportion of children and young people aged 12 to 18 years with type 2 diabetes who have had their smoking status recorded in the previous 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
This indicator covers the proportion of children and young people aged 12 to 18 years with type 1 diabetes who have had their smoking status recorded in the previous 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
This indicator covers the proportion of children and young people aged 12 to 18 years with type 2 diabetes who have a record of a foot examination in the previous 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
This indicator covers the proportion of children and young people aged 12 to 18 years with type 1 diabetes who have a record of a foot examination in the previous 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
This indicator covers the proportion of children and young people aged 12 to 18 years with type 2 diabetes who have a record of eye screening in the previous 24 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
This indicator covers the proportion of children and young people aged 12 to 18 years with type 1 diabetes who have a record of eye screening in the previous 24 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
This indicator covers the proportion of children and young people aged 12 to 18 years with type 1 diabetes who have had their urinary albumin recorded in the previous 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
This indicator covers the proportion of children and young people aged under 18 years with type 2 diabetes who have had their blood pressure recorded in the previous 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
This indicator covers the proportion of children and young people aged 12 to 18 years with type 1 diabetes who have had their blood pressure recorded in the previous 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
This indicator covers the proportion of children and young people aged under 18 years with type 2 diabetes who have had their BMI recorded in the previous 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
This indicator covers the proportion of children and young people aged under 18 years with type 1 diabetes who have had their BMI recorded in the previous 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
This indicator covers the proportion of children and young people aged under 18 years with type 2 diabetes who have had their glycated haemoglobin A1c (HbA1c) monitored in the previous 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
This indicator covers the proportion of children and young people aged under 18 years with type 1 diabetes who have had their glycated haemoglobin A1c (HbA1c) monitored in the previous 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
This indicator covers the proportion of children and young people aged 12 to 18 years with type 2 diabetes who received individual care processes in the previous 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes